Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

Similar articles for PubMed (Select 21325619)


A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM.

J Immunol. 2011 Mar 15;186(6):3606-14. doi: 10.4049/jimmunol.1003470. Epub 2011 Feb 16.


Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.

Costa I, Pajon R, Granoff DM.

MBio. 2014 Aug 26;5(5):e01625-14. doi: 10.1128/mBio.01625-14.


Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Granoff DM, Ram S, Beernink PT.

Clin Vaccine Immunol. 2013 Aug;20(8):1099-107. doi: 10.1128/CVI.00260-13. Epub 2013 Jun 5. Review.


Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.

Rossi R, Granoff DM, Beernink PT.

Vaccine. 2013 Nov 4;31(46):5451-7. doi: 10.1016/j.vaccine.2013.08.099. Epub 2013 Sep 11.


The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.


Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.

Giuntini S, Beernink PT, Reason DC, Granoff DM.

PLoS One. 2012;7(3):e34272. doi: 10.1371/journal.pone.0034272. Epub 2012 Mar 26.


Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.

Beernink PT, Shaughnessy J, Ram S, Granoff DM.

Clin Vaccine Immunol. 2010 Jul;17(7):1074-8. doi: 10.1128/CVI.00103-10. Epub 2010 Jun 2.


Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.

Pajon R, Beernink PT, Granoff DM.

Infect Immun. 2012 Aug;80(8):2667-77. doi: 10.1128/IAI.00103-12. Epub 2012 May 21. Erratum in: Infect Immun. 2014 Apr;82(4):1742.


The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S.

J Immunol. 2006 Jul 1;177(1):501-10.


Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Konar M, Granoff DM, Beernink PT.

J Infect Dis. 2013 Aug 15;208(4):627-36. doi: 10.1093/infdis/jit239. Epub 2013 May 28.


Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates.

van der Veen S, Johnson S, Jongerius I, Malik T, Genovese A, Santini L, Staunton D, Ufret-Vincenty RL, Pickering MC, Lea SM, Tang CM.

Infect Immun. 2014 Mar;82(3):1157-63. doi: 10.1128/IAI.01183-13. Epub 2013 Dec 30.


Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.


Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM.

Clin Vaccine Immunol. 2014 Nov;21(11):1505-11. doi: 10.1128/CVI.00517-14. Epub 2014 Sep 3.


Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.

Johnson S, Tan L, van der Veen S, Caesar J, Goicoechea De Jorge E, Harding RJ, Bai X, Exley RM, Ward PN, Ruivo N, Trivedi K, Cumber E, Jones R, Newham L, Staunton D, Ufret-Vincenty R, Borrow R, Pickering MC, Lea SM, Tang CM.

PLoS Pathog. 2012;8(10):e1002981. doi: 10.1371/journal.ppat.1002981. Epub 2012 Oct 25. Erratum in: PLoS Pathog. 2013 Jan;9(1). doi: 10.1371/annotation/3e7e6415-fb12-4a87-89e6-f87d2e800ba8.


Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Giuntini S, Reason DC, Granoff DM.

Infect Immun. 2011 Sep;79(9):3751-9. doi: 10.1128/IAI.05182-11. Epub 2011 Jun 27.


Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Giuntini S, Pajon R, Ram S, Granoff DM.

Infect Immun. 2015 Apr;83(4):1536-45. doi: 10.1128/IAI.02984-14. Epub 2015 Feb 2.


Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines.

Beernink PT, Granoff DM.

Infect Immun. 2008 Jun;76(6):2568-75. doi: 10.1128/IAI.00033-08. Epub 2008 Mar 24.


Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.

Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S.

MBio. 2013 Oct 15;4(5):e00339-13. doi: 10.1128/mBio.00339-13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk